TREMune Therapeutics is a clinical-stage biotechnology company pioneering targeted immunotherapies to halt the progression of devastating neurodegenerative diseases. Our therapies are designed to modulate immune responses in the central nervous system with the goal of delivering transformative outcomes for patients with conditions such as Alzheimer’s Disease, Parkinson’s disease, and Multiple System Atrophy.
OUR MISSION
We’re developing therapies that change the course of neurodegenerative diseases.
What Drives Us
TREMune Therapeutics was founded with the belief that neurodegeneration can be tackled by addressing the immune dysfunction at its core. Our name reflects our scientific foundation: targeting TREM2 and related pathways to unlock the protective power of microglia. Built on deep scientific insights and robust preclinical validation, we are advancing a pipeline of differentiated therapies with first-in-class and best-in-class potential.
OUR VISION
A future where neurodegenerative diseasesare no longer progressive but controllable - and ultimately curable - through precise, targeted modulation of the brain’s innate immune system.
Scientific Approach
TREMune Therapeutics is focused on modulating microglial activity to restore balance within the central nervous system. Our pipeline is grounded in the biology of TREM2 and alpha-synuclein—key targets implicated in neuroinflammation and proteinopathy. By activating or neutralizing specific immune responses, we aim to change the course of neurodegenerative disorders.
Our Pipeline
Candidate 1: CGX101
Targeting TREM2 in multiple neurodegenerative diseases
A first-in-class humanized IgG4 monoclonal antibody designed to activate TREM2 on microglia. By promoting microglial proliferation, activation, and phagocytosis, CGX101 aims to reduce neuronal loss and inflammation in neurodegenerative diseases. Supported by in vitro and in vivo data, CGX101 has shown survival benefit and neuroprotection in multiple animal models. The program is advancing toward GMP manufacturing and Phase I/II clinical trials.
Candidate 2: CGX208
Targeting Alpha-Synuclein in MSA & Parkinson’s
CGX208 is a novel scFv antibody, in both protein and AAV gene therapy formats, designed to neutralize toxic alpha-synuclein oligomers and fibrils. It addresses pathological protein spreading and neuroinflammation in MSA and Parkinson’s. Delivered intranasally or subcutaneously, CGX208 demonstrates strong target engagement, behavioural rescue, and neuroprotection in models. It is progressing toward Phase I/IIa studies.
Contact Us
We welcome enquiries from investors, collaborators, and clinicians. Tell us a little about your request, and the right person will respond.
© TREMune Therapeutics LLC 2025.